Altering microbial populations and modifying microbiota
AssigneeSNIPR Technologies Limited
InventorJasper Clube
Life of this patent
Estimating the term…
Abstract
The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling micro biologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.
Claims16
A method of treating or preventing a gastrointestinal condition in a human or animal subject, wherein the subject comprises a gut microbiota comprising Klebsiella bacteria cells, the method comprising administering to the subject an antimicrobial composition comprising an engineered nucleic acid for producing a host modifying crRNA (HM-crRNA) that selectively kills Klebsiella cells or inhibits the growth of Klebsiella cells in the microbiota,
- wherein
- (i) the HM-crRNA is operable with a Cas in the Klebsiella cells, wherein the engineered nucleic acid and the Cas are comprised by a HM-CRISPR/Cas system in the Klebsiella cells;
- and
- (ii) the HM-crRNA comprises a nucleotide sequence that is capable of hybridizing to a target sequence in the Klebsiella cells to guide the Cas to cut the target sequence in the Klebsiella cells, thereby killing Klebsiella cells or inhibiting the growth of Klebsiella cells in the microbiota.
A method of treating or preventing an IBD in a human or animal subject, wherein the subject comprises a gut microbiota comprising Klebsiella bacteria cells, the method comprising administering to the subject an antimicrobial composition comprising an engineered nucleic acid for producing a host modifying crRNA (HM-crRNA) that selectively kills Klebsiella cells or inhibits the growth of Klebsiella cells in the microbiota, thereby decreasing the proportion of Klebsiella cells in the microbiota,
- wherein the antimicrobial composition further comprises an engineered nucleic acid for producing a guided nuclease to selectively target the genome of the Klebsiella cells and allowing the guided nuclease to cut one or more target nucleotide sequences comprised by the Klebsiella cells, and
- wherein
- (i) the HM-crRNA is operable with a Cas in the Klebsiella cells, wherein the engineered nucleic acid and the Cas are comprised by a HM-CRISPR/Cas system in the Klebsiella cells;
- and
- (ii) the HM-crRNA comprises a nucleotide sequence that is capable of hybridizing to a target sequence in the Klebsiella cells to guide the Cas to cut the target sequence in the Klebsiella cells, thereby killing Klebsiella cells or inhibiting the growth of Klebsiella cells in the microbiota.
A method of treating or preventing an IBD in a human or animal subject, wherein the subject comprises a gut microbiota comprising Klebsiella bacteria cells, the method comprising administering to the subject phages that infect and selectively kill Klebsiella cells or inhibit the growth of Klebsiella cells in the microbiota, thereby decreasing the proportion of Klebsiella cells in the microbiota,
- wherein the phages comprise an engineered nucleic acid for producing a host modifying crRNA (HM-crRNA),
- wherein the phages further comprise an engineered nucleic acid for producing a guided nuclease to selectively target the genome of the Klebsiella cells and allowing the guided nuclease to cut one or more target nucleotide sequences comprised by the Klebsiella cells, and
- wherein
- (i) the HM-crRNA is operable with a Cas in the Klebsiella cells, wherein the engineered nucleic acid and the Cas are comprised by a HM-CRISPR/Cas system in the Klebsiella cells;
- and
- (ii) the HM-crRNA comprises a nucleotide sequence that is capable of hybridizing to a target sequence in the Klebsiella cells to guide the Cas to cut the target sequence in the Klebsiella cells, thereby killing Klebsiella cells or inhibiting the growth of Klebsiella cells in the microbiota.
A method of treating or preventing an IBD in a human or animal subject, wherein the subject comprises a gut microbiota comprising K. pneumoniae bacteria cells, the method comprising:
- (a) contacting the K. pneumoniae cells in the microbiota with an engineered nucleic acid for producing a host modifying crRNA (HM-crRNA), and
- (b) producing the HM-crRNA in the K. pneumoniae cells;
- wherein
- (i) the HM-crRNA is operable with a Cas in the K. pneumoniae cells, wherein the engineered nucleic acid and the Cas are comprised by a HM-CRISPR/Cas system in the K. pneumoniae cells;
- (ii) the HM-crRNA comprises a nucleotide sequence that is capable of hybridizing to a target sequence in the K. pneumoniae cells to guide the Cas to cut the target sequence in the K. pneumoniae cells, thereby killing K. pneumoniae cells or inhibiting the growth of K. pneumoniae cells in the microbiota, whereby the proportion of K. pneumoniae cells in the microbiota is decreased.
Dependencies are inferred from the claim text.